‹ Screener

Vivani Medical, Inc.

VANI · Electromedical & Electrotherapeutic Apparatus · 86.2M shares · +8%/yr ↑ dilution · EDGAR filings ↗

Reference price $1.26 · est. market cap ~$109M — last insider purchase, 2026-06-15 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

D44

Vivani Medical — clinical-stage implantable drug-delivery developer near cash-out.

Strengths

Risks

Notable findings

Quarterly revenue

2015-06-30 · $3M2015-09-30 · $2M2015-12-31 · $2M2016-03-31 · $1K

Last 4 quarters · from SEC filings.

Key metrics

Return on equity
-169.2%
Return on assets
-67.5%
Revenue growth (QoQ)
-100.0%
Current ratio
2.7×
Free cash flow
-$25M
EBITDA
-$27M
Tangible book value
$16M
Cash & investments
$16M
Cash runway
2q

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-06-15Williams GreggBuy1.6M$1.26
2026-05-15Williams GreggBuy1.6M$1.26
2026-04-15Williams GreggBuy1.6M$1.26
2026-03-15Williams GreggBuy1.3M$1.03
2026-03-15Williams GreggBuy265K$1.26
2026-02-15Williams GreggBuy1.6M$1.03
2026-02-15Williams GreggBuy265K$1.26
2026-01-27Williams GreggBuy1.4M$1.48
2026-01-15Williams GreggBuy1.5M$1.12
2026-01-15Williams GreggBuy265K$1.26
2025-12-29Mendelsohn AaronBuy20K$1.23
2025-12-15Williams GreggBuy1.5M$1.12
2025-12-15Williams GreggBuy265K$1.26
2025-11-15Williams GreggBuy1.5M$1.12
2025-11-15Williams GreggBuy265K$1.26
2025-10-27Williams GreggBuy3.7M$1.62
2025-10-15Williams GreggBuy1.5M$1.12
2025-10-15Williams GreggBuy265K$1.26
2025-09-15Williams GreggBuy1.5M$1.12
2025-09-15Williams GreggBuy595K$1.26
2025-05-16Williams GreggBuy2.4K$1.01
2025-05-15Williams GreggBuy6.8K$1.01
2025-05-14Williams GreggBuy3.5K$1.01
2025-04-24Williams GreggBuy1.1K$1.01
2025-04-22Williams GreggBuy243$1.01
2025-04-21Williams GreggBuy1.6K$1.01
2025-04-11Williams GreggBuy2.3K$1.01
2025-04-09Williams GreggBuy19K$1.02
2025-04-08Williams GreggBuy63K$1.02
2025-04-07Williams GreggBuy59K$0.99
2025-04-07Williams GreggBuy44K$0.99
2025-04-04Williams GreggBuy34K$0.99
2025-04-04Williams GreggBuy5.6K$0.98
2025-04-03Williams GreggBuy23K$1.00
2025-04-02Williams GreggBuy2.0K$1.01
2025-04-01Dwyer DonaldBuy4.0K$1.02
2025-02-28Dwyer DonaldBuy1.0K$1.11

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT07430059 ↗Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Obesity & Overweight
PHASE1Not Yet Recruiting2026-08-01
NCT05670379 ↗Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
Overweight and Obesity, Type2diabetes
PHASE1Completed2025-08-21

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Notable events (8-K)

DateItems
2026-06-04Reg FDExhibitsfiling ↗
2026-05-13ResultsReg FDExhibitsfiling ↗
2026-03-26ResultsExhibitsfiling ↗
2026-01-27Material agreement3.02Reg FDExhibitsfiling ↗
2025-11-13ResultsReg FDExhibitsfiling ↗
2025-10-28Material agreement3.02Reg FDExhibitsfiling ↗
2025-10-03Reg FDOtherExhibitsfiling ↗
2025-09-17OtherExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-06-042026-06-040001753926-26-000974 ↗
10-Q2026-05-132026-03-310001753926-26-000852 ↗
8-K2026-05-132026-05-130001753926-26-000854 ↗
8-K2026-03-262026-03-260001753926-26-000550 ↗
10-K2026-03-262025-12-310001753926-26-000548 ↗
8-K2026-01-272026-01-250001753926-26-000194 ↗
8-K2025-11-132025-11-130001753926-25-001768 ↗
10-Q2025-11-132025-09-300001753926-25-001770 ↗
8-K2025-10-282025-10-260001753926-25-001655 ↗
8-K2025-10-032025-10-030001753926-25-001582 ↗
8-K2025-09-172025-09-170001753926-25-001510 ↗
8-K2025-09-092025-09-090001753926-25-001443 ↗